Session Information
Date: Thursday, June 8, 2017
Session Title: Other
Session Time: 1:15pm-2:45pm
Location: Exhibit Hall C
Objective: To analyze clinical progression at enrolment in drug-naïve Parkinson’s disease (PD) subjects over 48 months of follow-up, we describe the annual rate of progression and identify baseline factors that may influence progression dynamic.
Background: Predictors for different motor progression of PD may indicate biological processes related to disease activity and assist to design clinical trials aimed at neuroprotection in PD.
Methods: Longitudinal study on recently diagnosed PD subjects of the single center De Novo Parkinson (DeNoPa) cohort (1,2). The Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS total and III), Mini Mental Status Examination (MMSE) and the quality of life questionnaire (PDQ-39) from baseline, 24- and 48-months follow-up were investigated in PD subjects. A panel of 50 assessments at baseline were explored as predictors for motor progression of the disease. These included socio demographics, non-motor motor symptoms, cardio vascular risk factors, imaging, blood, and cerebrospinal fluid (CSF) analyses.
Results: A total of 117 PD subjects (76 males, 41 females) with a mean age of 63.7±9.6 years were recruited and followed. MDS-UPDRS part III and the total score progressed over the four-year follow-up with an annual rate of change of 2.0 (part III) and 5.4 (total) points. The significant baseline predictors for a more severe motor progression by MDS-UPDRS III were male gender, high systolic blood pressure, comorbidity of coronary artery disease, as well as elevated neurofilament light chains in CSF.
Conclusions: We conclude that cardiovascular parameters may be involved in the progression dynamics of PD patients within 24 and 48 months of diagnosis. CSF light chain represents more severe axonal degeneration. Our panel of risk parameters needs validation during our continuing follow-up but also by independent groups.
References: (1) Mollenhauer B, et al. Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology. 2013;81:1226-34.
(2) Mollenhauer B, et al. Monitoring of 30 marker candidates in early Parkinson disease as progression markers. Neurology. 2016;87:168-77.
To cite this abstract in AMA style:
B. Mollenhauer, J. Zimmermann, F. Sixel-Döring, N. Focke, T. Wicke, J. Ebentheuer, M. Schaumburg, E. Lang, C. Trenkwalder. Baseline predictors for clinical progression after 48 month follow-up in early Parkinson’s disease from the DeNoPa cohort [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/baseline-predictors-for-clinical-progression-after-48-month-follow-up-in-early-parkinsons-disease-from-the-denopa-cohort/. Accessed June 14, 2025.« Back to 2017 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/baseline-predictors-for-clinical-progression-after-48-month-follow-up-in-early-parkinsons-disease-from-the-denopa-cohort/